chartexchange

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026

GlobeNewswire Inc. | Nov 16, 2026 4:00 PM EST

– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –

Read original article